医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
15期
210-210
,共1页
万拉法新%焦虑症%氯硝安定%治疗结果
萬拉法新%焦慮癥%氯硝安定%治療結果
만랍법신%초필증%록초안정%치료결과
Venlafaxine%Anxiety%Clonazepam
目的：评价万拉法新治疗广泛性焦虑症的临床疗效和副作用。方法将76例符合CCMD--3诊断标准的广泛性焦虑症病人，随机分为两组，分别应用万拉法新(38例)、氯硝安定(38例)进行治疗，疗程6周。采用焦虑自评量表(SAS)、Hamilton焦虑量表(HAMA)和副作用量表(TESS)评定疗效和副作用。结果万拉法新与氯硝安定对广泛性焦虑症均有显著疗效，两组间疗效差异无显著性(P＞0.05)，万拉法新副作用明显少于氯硝安定仲(P<0.01)。结论万拉法新治疗广泛性焦虑症安全有效，副作用少。
目的：評價萬拉法新治療廣汎性焦慮癥的臨床療效和副作用。方法將76例符閤CCMD--3診斷標準的廣汎性焦慮癥病人，隨機分為兩組，分彆應用萬拉法新(38例)、氯硝安定(38例)進行治療，療程6週。採用焦慮自評量錶(SAS)、Hamilton焦慮量錶(HAMA)和副作用量錶(TESS)評定療效和副作用。結果萬拉法新與氯硝安定對廣汎性焦慮癥均有顯著療效，兩組間療效差異無顯著性(P＞0.05)，萬拉法新副作用明顯少于氯硝安定仲(P<0.01)。結論萬拉法新治療廣汎性焦慮癥安全有效，副作用少。
목적：평개만랍법신치료엄범성초필증적림상료효화부작용。방법장76례부합CCMD--3진단표준적엄범성초필증병인，수궤분위량조，분별응용만랍법신(38례)、록초안정(38례)진행치료，료정6주。채용초필자평량표(SAS)、Hamilton초필량표(HAMA)화부작용량표(TESS)평정료효화부작용。결과만랍법신여록초안정대엄범성초필증균유현저료효，량조간료효차이무현저성(P＞0.05)，만랍법신부작용명현소우록초안정중(P<0.01)。결론만랍법신치료엄범성초필증안전유효，부작용소。
Objective To evaluate the efficacy and side effects of venlafaxine in the treatment of general anxiety disorder.Methods 76 patients who met the criteria of CCMD-3 for generalized anxiety disorder were randomly assigned into venlafaxine group and clonazepam group for treatment of 6 weeks.The effects and side effects of two groups were assessed by HAMD,SAS and TESS Results Both drugs had marked efficacy in the treatment of generalized anxiety disorder. Conclusion Venlafaxine is a safe and efficient drug with fewer side effects for the treatment of generalized anxiety disorder.
